BRIEF published on 05/14/2025 at 22:20, 1 year 1 month ago Bausch Health annonce les résultats des élections et les approbations lors de son assemblée annuelle 2025 Bausch Santé Vote Des Actionnaires Élection Du Directeur Assemblée Annuelle Approbation De L'indemnisation
BRIEF published on 05/14/2025 at 22:20, 1 year 1 month ago Bausch Health Announces Election Results and Approvals at 2025 Annual Meeting Bausch Health Annual Meeting Shareholder Vote Director Election Compensation Approval
PRESS RELEASE published on 05/14/2025 at 22:15, 1 year 1 month ago Bausch Health Announces 2025 Annual Meeting of Shareholder Results Bausch Health Companies Inc. announces election of 10 directors at 2025 annual meeting of shareholders and various approvals and appointments Shareholders Bausch Health Companies Inc. Compensation Annual Meeting Election Of Directors
BRIEF published on 05/06/2025 at 14:05, 1 year 1 month ago Xifaxan Reduces Risk of 30-Day Rehospitalization After OHE XIFAXAN Chronic Liver Disease OHE Rehospitalization Claims-Based Analysis Lactulose
BRIEF published on 05/06/2025 at 14:05, 1 year 1 month ago Xifaxan réduit le risque de réhospitalisation dans les 30 jours suivant une OHE XIFAXAN Maladie Chronique Du Foie Lactulose Réhospitalisation OHE Analyse Basée Sur Les Réclamations
PRESS RELEASE published on 05/06/2025 at 14:00, 1 year 1 month ago Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization New analysis shows Xifaxan efficacy in reducing OHE rehospitalizations regardless of prior treatment. Data presented at DDW 2025 XIFAXAN Bausch Health Gastroenterology OHE Rehospitalizations
BRIEF published on 04/30/2025 at 22:10, 1 year 1 month ago Bausch Health Reports First-Quarter 2025 Results Financial Results EBITDA Revenue Growth Bausch Health First Quarter 2025
BRIEF published on 04/30/2025 at 22:10, 1 year 1 month ago Bausch Health publie ses résultats du premier trimestre 2025 Résultats Financiers EBITDA Croissance Des Revenus Bausch Santé Premier Trimestre 2025
PRESS RELEASE published on 04/30/2025 at 22:05, 1 year 1 month ago Bausch Health Announces First Quarter 2025 Results Bausch Health Companies Inc. reports strong first quarter 2025 financial results with revenue growth, successful refinancing, and favorable court ruling. Company remains focused on profitable growth and shareholder value Financial Results Revenue Growth Shareholder Value Bausch Health First Quarter 2025
BRIEF published on 04/29/2025 at 14:05, 1 year 1 month ago Bausch Health Secures Health Canada Approval for Thermage FLX Thermage FLX Bausch Health Health Canada Aesthetic Technology Skin Tightening
Published on 06/27/2026 at 16:50, 50 minutes ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 16 hours ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 17 hours 40 minutes ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 18 hours 40 minutes ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 18 hours 50 minutes ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/27/2026 at 00:05, 17 hours 34 minutes ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 17 hours 35 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 18 hours 4 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 18 hours 4 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 18 hours 12 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
Published on 06/26/2026 at 17:45, 23 hours 55 minutes ago Descriptif du programme de rachat d'actions
